Submitted by Anonymous (not verified) on 19 February 2026 - 14:10
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised
Source: